Senile cataract
disease diseaseOn this page
Summary
Senile cataract (MONDO:0004847) is a disease with 30 GWAS associations across 13 studies and 10 clinical trials. A subtype of cataract — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 30
- Clinical trials: 10
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | senile cataract |
| Mondo ID | MONDO:0004847 |
| DOID | DOID:9669 |
| ICD-10-CM | H25 |
| NCIT | C35012 |
| SNOMED CT | 39450006 |
| UMLS | C0036646 |
| MedGen | 11372 |
| Is cancer (heuristic) | no |
Data availability: 30 GWAS associations (13 studies).
Disease family
This is a subtype of cataract. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › lens disorder › cataract › senile cataract
Related subtypes (28): immature cataract, diabetic cataract, mature cataract, tetanic cataract, myotonic cataract, diabetes mellitus type 2 associated cataract, cataract 4 multiple types, cataract 29, cataract 1 multiple types, early-onset non-syndromic cataract, cataract 3 multiple types, cataract 9 multiple types, cataract 28, cataract 18, cataract 12 multiple types, cataract 34 multiple types, cataract 36, bhaskar jagannathan syndrome, autosomal dominant cataract, craniostenosis cataract, Kozlowski Rafinski Klicharska syndrome, cataract 49, cataract 48, hypermature cataract, nuclear cataract, cortical cataract, cataract 2, multiple types, cataract 50 with or without glaucoma
Subtypes (2): cortical senile cataract, nuclear senile cataract
Genetics & variants
GWAS landscape
30 GWAS associations across 13 studies. Top hits map to 2 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr20:19496121 | 2e-26 | A | 0.12 | |
| chr7:46174655 | 2e-20 | G | 0.08 | |
| chr11:187382 | 1e-19 | T | 0.11 | |
| chr11:69176395 | 3e-19 | C | 0.12 | |
| chr4:173984049 | 1e-16 | T | 0.83 | |
| chr9:22206988 | 1e-15 | T | 0.07 | |
| rs34872471 | 2e-15 | TCF7L2 | T | 0.04 |
| chr15:28288419 | 3e-15 | C | 0.08 | |
| chr3:181650240 | 2e-14 | GT | 0.06 | |
| chr17:81619201 | 7e-13 | T | 0.06 | |
| chr7:127375029 | 2e-12 | A | 0.19 | |
| chr1:227014170 | 3e-11 | G | 0.05 | |
| chr16:7410698 | 4e-11 | G | 0.06 | |
| chr17:137198 | 4e-10 | C | 0.12 | |
| chr20:10669037 | 7e-10 | AAAT | 0.06 | |
| chr11:65850567 | 1e-09 | A | 1.85 | |
| chr17:83107711 | 3e-09 | T | 0.05 | |
| chr10:122454164 | 6e-09 | A | 0.06 | |
| chr8:9457113 | 1e-08 | C | 0.84 | |
| chr2:217531737 | 1e-08 | G | 0.05 | |
| chr1:169071933 | 2e-08 | C | 0.05 | |
| chr17:63876118 | 2e-08 | C | 0.89 | |
| chr7:125793019 | 3e-08 | C | 0.53 | |
| chrX:67086946 | 3e-08 | A | 2.23 | |
| chr6:163431493 | 4e-08 | C | 0.05 | |
| chr14:43814883 | 4e-08 | A | 0.23 | |
| chr17:13999386 | 4e-08 | G | 2.29 | |
| chr16:86675135 | 5e-08 | A | 0.05 | |
| chrX:65102561 | 5e-08 | A | 1.86 | |
| rs56216435 | 2e-07 | SDK2 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90477674 | Verma A | 2024 | 197,600 | 206,486 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477673 | Verma A | 2024 | 53,129 | 53,452 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480071 | Verma A | 2024 | 53,129 | 53,452 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90473410 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 34,058 | 424,382 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667821 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 34,058 | 424,382 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90477671 | Verma A | 2024 | 20,660 | 33,135 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435987 | Zhou W | 2018 | 8,369 | 388,609 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90651926 | Liu TY | 2025 | 5,960 | 223,893 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90477672 | Verma A | 2024 | 2,197 | 4,058 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90726851 | Kim HI | 2026 | 1,252 | 42,774 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 30 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 2 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 28 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 28 |
| intron_variant | 2 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr20:19496121 | 2e-26 | Tier 4: intronic/intergenic | ||||||
| chr7:46174655 | 2e-20 | Tier 4: intronic/intergenic | ||||||
| chr11:187382 | 1e-19 | Tier 4: intronic/intergenic | ||||||
| chr11:69176395 | 3e-19 | Tier 4: intronic/intergenic | ||||||
| chr4:173984049 | 1e-16 | Tier 4: intronic/intergenic | ||||||
| chr9:22206988 | 1e-15 | Tier 4: intronic/intergenic | ||||||
| rs34872471 | 10 | 112994312 | T>C | 0.296 | intron_variant | TCF7L2 | 2e-15 | Tier 4: intronic/intergenic |
| chr15:28288419 | 3e-15 | Tier 4: intronic/intergenic | ||||||
| chr3:181650240 | 2e-14 | Tier 4: intronic/intergenic | ||||||
| chr17:81619201 | 7e-13 | Tier 4: intronic/intergenic | ||||||
| chr7:127375029 | 2e-12 | Tier 4: intronic/intergenic | ||||||
| chr1:227014170 | 3e-11 | Tier 4: intronic/intergenic | ||||||
| chr16:7410698 | 4e-11 | Tier 4: intronic/intergenic | ||||||
| chr17:137198 | 4e-10 | Tier 4: intronic/intergenic | ||||||
| chr20:10669037 | 7e-10 | Tier 4: intronic/intergenic | ||||||
| chr11:65850567 | 1e-09 | Tier 4: intronic/intergenic | ||||||
| chr17:83107711 | 3e-09 | Tier 4: intronic/intergenic | ||||||
| chr10:122454164 | 6e-09 | Tier 4: intronic/intergenic | ||||||
| chr8:9457113 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr2:217531737 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr1:169071933 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr17:63876118 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr7:125793019 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chrX:67086946 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr6:163431493 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr14:43814883 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr17:13999386 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr16:86675135 | 5e-08 | Tier 4: intronic/intergenic | ||||||
| chrX:65102561 | 5e-08 | Tier 4: intronic/intergenic | ||||||
| rs56216435 | 17 | 73457507 | C>A,G,T | 0.05 | intron_variant | SDK2 | 2e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 10.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 10 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02966496 | Not specified | UNKNOWN | Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract |
| NCT03050008 | Not specified | COMPLETED | Efficacy of FLACS USFREE Compared to Traditional Surgery Using Ultrasound. |
| NCT03262285 | Not specified | COMPLETED | Corneal Endothelial Cell Loss After Phacoemulsification Compared With Extracapsular Cataract Extraction |
| NCT03766230 | Not specified | UNKNOWN | Clinical Study on Second-eye Pain in Cataract Surgery |
| NCT04468308 | Not specified | UNKNOWN | VRQOL in Cataract Patients During the COVID-19 Pandemic |
| NCT04972435 | Not specified | COMPLETED | Effect of Multifocal Intraocular Lens on Contrast Sensitivity in Primary Angle-Closure Patients |
| NCT05014269 | Not specified | COMPLETED | Phacoemulsification in Patients With Corneal Opacities |
| NCT05646004 | Not specified | COMPLETED | 621 Real World Study |
| NCT06192901 | Not specified | COMPLETED | Safety and Performance of Hydrophobic and Hydrophilic Intraocular Lenses After Bilateral Cataract Surgery |
| NCT06383754 | Not specified | COMPLETED | Clareon Intraocular Lens Stability in Vitrectomy Patients: CLOVE Study |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.